Advertisement

Acta Neuropathologica

, Volume 122, Issue 3, pp 285–292 | Cite as

Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Aβ and tau pathology in transgenic mouse models of Alzheimer’s disease

  • Charles Y. Shao
  • Suzanne S. Mirra
  • Hameetha B. R. Sait
  • Todd C. Sacktor
  • Einar M. Sigurdsson
Original Paper

Abstract

Impairment of synaptic plasticity underlies memory dysfunction in Alzheimer’s disease (AD). Molecules involved in this plasticity such as PSD-95, a major postsynaptic scaffold protein at excitatory synapses, may play an important role in AD pathogenesis. We examined the distribution of PSD-95 in transgenic mice of amyloidopathy (5XFAD) and tauopathy (JNPL3) as well as in AD brains using double-labeling immunofluorescence and confocal microscopy. In wild type control mice, PSD-95 primarily labeled neuropil with distinct distribution in hippocampal apical dendrites. In 3-month-old 5XFAD mice, PSD-95 distribution was similar to that of wild type mice despite significant Aβ deposition. However, in 6-month-old 5XFAD mice, PSD-95 immunoreactivity in apical dendrites markedly decreased and prominent immunoreactivity was noted in neuronal soma in CA1 neurons. Similarly, PSD-95 immunoreactivity disappeared from apical dendrites and accumulated in neuronal soma in 14-month-old, but not in 3-month-old, JNPL3 mice. In AD brains, PSD-95 accumulated in Hirano bodies in hippocampal neurons. Our findings support the notion that either Aβ or tau can induce reduction of PSD-95 in excitatory synapses in hippocampus. Furthermore, this PSD-95 reduction is not an early event but occurs as the pathologies advance. Thus, the time-dependent PSD-95 reduction from synapses and accumulation in neuronal soma in transgenic mice and Hirano bodies in AD may mark postsynaptic degeneration that underlies long-term functional deficits.

Keywords

PSD-95 Alzheimer’s disease Transgenic mice 5XFAD JNPL3 P301L Hippocampus Hirano body 

Abbreviations

PSD-95

Postsynaptic density 95

AD

Alzheimer’s disease

5XFAD

Five familial AD mutations

JNPL3

Founder line of P301L mice that express human tau encoding the frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)

CA1

Cornu Ammonis area 1 of hippocampus

Notes

Acknowledgments

This work was supported by NIH Grants R01 AG020197 and R01 AG032611, and the Alzheimer’s Association to E.M.S., and by NIH Grants RO1 MH53576 and MH57068 to T.C.S.

References

  1. 1.
    Almeida CG, Tampellini D, Takahashi RH et al (2005) Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis 20:187–198PubMedCrossRefGoogle Scholar
  2. 2.
    Aronica E, Dickson DW, Kress Y, Morrison JH, Zukin RS (1998) Non-plaque dystrophic dendrites in Alzheimer hippocampus: a new pathological structure revealed by glutamate receptor immunocytochemistry. Neuroscience 82:979–991PubMedCrossRefGoogle Scholar
  3. 3.
    Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27:9115–9129PubMedCrossRefGoogle Scholar
  4. 4.
    Blanpied TA, Kerr JM, Ehlers MD (2008) Structural plasticity with preserved topology in the postsynaptic protein network. Proc Natl Acad Sci USA 105:12587–12592PubMedCrossRefGoogle Scholar
  5. 5.
    Boekhoorn K, Terwel D, Biemans B et al (2006) Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy. J Neurosci 26:3514–3523PubMedCrossRefGoogle Scholar
  6. 6.
    Chen X, Winters C, Azzam R et al (2008) Organization of the core structure of the postsynaptic density. Proc Natl Acad Sci USA 105:4453–4458PubMedCrossRefGoogle Scholar
  7. 7.
    Crary JF, Shao CY, Mirra SS, Hernandez AI, Sacktor TC (2006) Atypical protein kinase C in neurodegenerative disease I: PKMzeta aggregates with limbic neurofibrillary tangles and AMPA receptors in Alzheimer disease. J Neuropathol Exp Neurol 65:319–326PubMedCrossRefGoogle Scholar
  8. 8.
    Davies CA, Mann DM, Sumpter PQ, Yates PO (1987) A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer’s disease. J Neurol Sci 78:151–164PubMedCrossRefGoogle Scholar
  9. 9.
    DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol 27:457–464PubMedCrossRefGoogle Scholar
  10. 10.
    Dickson DW, Crystal HA, Bevona C et al (1995) Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16:285–298 (discussion 98–304)PubMedCrossRefGoogle Scholar
  11. 11.
    El-Husseini Ael D, Schnell E, Dakoji S et al (2002) Synaptic strength regulated by palmitate cycling on PSD-95. Cell 108:849–863CrossRefGoogle Scholar
  12. 12.
    Fischer P, Jungwirth S, Zehetmayer S et al (2007) Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology 68:288–291PubMedCrossRefGoogle Scholar
  13. 13.
    Galloway PG, Perry G, Gambetti P (1987) Hirano body filaments contain actin and actin-associated proteins. J Neuropathol Exp Neurol 46:185–199PubMedCrossRefGoogle Scholar
  14. 14.
    Goldman JE (1983) The association of actin with Hirano bodies. J Neuropathol Exp Neurol 42:146–152PubMedCrossRefGoogle Scholar
  15. 15.
    Gylys KH, Fein JA, Yang F et al (2004) Synaptic changes in Alzheimer’s disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am J Pathol 165:1809–1817PubMedCrossRefGoogle Scholar
  16. 16.
    Hirano A (1994) Hirano bodies and related neuronal inclusions. Neuropathol Appl Neurobiol 20:3–11PubMedCrossRefGoogle Scholar
  17. 17.
    Hirano A, Dembitzer HM, Kurland LT, Zimmerman HM (1968) The fine structure of some intraganglionic alterations. Neurofibrillary tangles, granulovacuolar bodies and “rod-like” structures as seen in Guam amyotrophic lateral sclerosis and parkinsonism-dementia complex. J Neuropathol Exp Neurol 27:167–182PubMedCrossRefGoogle Scholar
  18. 18.
    Hunt CA, Schenker LJ, Kennedy MB (1996) PSD-95 is associated with the postsynaptic density and not with the presynaptic membrane at forebrain synapses. J Neurosci 16:1380–1388PubMedGoogle Scholar
  19. 19.
    Kimura R, Ohno M (2009) Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol Dis 33:229–235PubMedCrossRefGoogle Scholar
  20. 20.
    Lacor PN, Buniel MC, Chang L et al (2004) Synaptic targeting by Alzheimer’s-related amyloid beta oligomers. J Neurosci 24:10191–10200PubMedCrossRefGoogle Scholar
  21. 21.
    Leuba G, Savioz A, Vernay A et al (2008) Differential changes in synaptic proteins in the Alzheimer frontal cortex with marked increase in PSD-95 postsynaptic protein. J Alzheimers Dis 15:139–151PubMedGoogle Scholar
  22. 22.
    Leuba G, Walzer C, Vernay A et al (2008) Postsynaptic density protein PSD-95 expression in Alzheimer’s disease and okadaic acid induced neuritic retraction. Neurobiol Dis 30:408–419PubMedCrossRefGoogle Scholar
  23. 23.
    Lewis J, McGowan E, Rockwood J et al (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25:402–405PubMedCrossRefGoogle Scholar
  24. 24.
    Love S, Siew LK, Dawbarn D et al (2006) Premorbid effects of APOE on synaptic proteins in human temporal neocortex. Neurobiol Aging 27:797–803PubMedCrossRefGoogle Scholar
  25. 25.
    Masliah E, Mallory M, Alford M et al (2001) Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease. Neurology 56:127–129PubMedGoogle Scholar
  26. 26.
    Masliah E, Terry RD, Alford M, DeTeresa R, Hansen LA (1991) Cortical and subcortical patterns of synaptophysin like immunoreactivity in Alzheimer’s disease. Am J Pathol 138:235–246PubMedGoogle Scholar
  27. 27.
    Mirra SS, Heyman A, McKeel D et al (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486PubMedGoogle Scholar
  28. 28.
    Oakley H, Cole SL, Logan S et al (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26:10129–10140PubMedCrossRefGoogle Scholar
  29. 29.
    Ohno M (2009) Failures to reconsolidate memory in a mouse model of Alzheimer’s disease. Neurobiol Learn Mem 92:455–459PubMedCrossRefGoogle Scholar
  30. 30.
    Peterson C, Kress Y, Vallee R, Goldman JE (1988) High molecular weight microtubule-associated proteins bind to actin lattices (Hirano bodies). Acta Neuropathol (Berl) 77:168–174Google Scholar
  31. 31.
    Proctor DT, Coulson EJ, Dodd PR (2010) Reduction in post-synaptic scaffolding PSD-95 and SAP-102 protein levels in the Alzheimer inferior temporal cortex is correlated with disease pathology. J Alzheimers Dis 21:795–811PubMedGoogle Scholar
  32. 32.
    Ramsden M, Kotilinek L, Forster C et al (2005) Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 25:10637–10647PubMedCrossRefGoogle Scholar
  33. 33.
    Selkoe DJ (1994) Alzheimer’s disease: a central role for amyloid. J Neuropathol Exp Neurol 53:438–447PubMedCrossRefGoogle Scholar
  34. 34.
    Shao CY, Crary JF, Rao C, Sacktor TC, Mirra SS (2006) Atypical protein kinase C in neurodegenerative disease II: PKCiota/lambda in tauopathies and alpha-synucleinopathies. J Neuropathol Exp Neurol 65:327–335PubMedCrossRefGoogle Scholar
  35. 35.
    Siew LK, Love S, Dawbarn D, Wilcock GK, Allen SJ (2004) Measurement of pre- and post-synaptic proteins in cerebral cortex: effects of post-mortem delay. J Neurosci Methods 139:153–159PubMedCrossRefGoogle Scholar
  36. 36.
    Sjostrom PJ, Rancz EA, Roth A, Hausser M (2008) Dendritic excitability and synaptic plasticity. Physiol Rev 88:769–840PubMedCrossRefGoogle Scholar
  37. 37.
    Sze CI, Troncoso JC, Kawas C et al (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 56:933–944PubMedCrossRefGoogle Scholar
  38. 38.
    Terry RD, Masliah E, Salmon DP et al (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572–580PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Charles Y. Shao
    • 1
  • Suzanne S. Mirra
    • 1
  • Hameetha B. R. Sait
    • 3
    • 4
  • Todd C. Sacktor
    • 2
  • Einar M. Sigurdsson
    • 3
    • 4
  1. 1.Department of PathologySUNY Downstate Medical CenterBrooklynUSA
  2. 2.Department of Physiology, Pharmacology and NeurologySUNY Downstate Medical CenterBrooklynUSA
  3. 3.Department of Physiology and NeuroscienceNYU School of MedicineNew YorkUSA
  4. 4.Department of PsychiatryNYU School of MedicineNew YorkUSA

Personalised recommendations